Evidence map›Paper›PMID 41669855›Full record

ArticleThe Journal of clinical endocrinology and metabolism2026

Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes.

Andrea Ortiz Rocha, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Diana Barb, Fernando Bril, Stephen A Marangi, Helena B Thomaides-Brears, Jens T Rosenberg, Nathaly Cuervo-Pardo, Romina Lomonaco and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrea Ortiz RochaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.ORCID 0009-0001-9192-9442
Srilaxmi KalavalapalliDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.ORCID 0009-0000-7009-264X
Eddison Godinez LeivaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.ORCID 0009-0000-9936-0206
Diana BarbDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.ORCID 0000-0001-5208-6828
Fernando BrilDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA.ORCID 0000-0001-5570-4396
Stephen A MarangiDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.
Helena B Thomaides-BrearsPerspectum, Gemini One, 5520 John Smith Drive, Oxford, OX4 2LL, UK.
Jens T RosenbergAdvanced Magnetic Resonance Imaging and Spectroscopy Facility, McKnight Brain Institute, University of Florida at Gainesville, FL 32610, USA.
Nathaly Cuervo-PardoDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.
Romina LomonacoDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.
Enrique Valdez SaenzDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.
Anu SharmaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.ORCID 0000-0002-0435-2201
Kenneth CusiDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville, FL 32610, USA.ORCID 0000-0002-8629-418X

Funding

InventivaNIH HHS DK-120331Perspectum
6 · The paper itself

Abstract

contextMultiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH).

objectiveIn type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear.

methodsWe recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild-moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE).

resultsHigher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001).

conclusionIn people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.

Indexed as

Diabetes Mellitus, Type 2Fatty LiverInsulin ResistanceMagnetic Resonance ImagingMetabolic SyndromeNon-alcoholic Fatty Liver DiseaseAgedCardiometabolic Risk FactorsFemaleHumansIronLiverMaleMiddle AgedSeverity of Illness IndexIroncT1diabetes mellitus type 2imagingliver fibrosisMASLD/NAFLDMRE

Identifiers

PMID41669855
PMCPMC13271803

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.